CYTOFLUORIMETRIC MONITORING OF MINIMAL RESIDUAL DISEASE CAN PREDICT CLINICAL REMISSION IN MULTIPLE MYELOMA PATIENTS UNDERGOING NON MYELOABLATIVE ALLOGENEIC TRANSPLANTATION